After Loper Bright, Round Two: The 2026 Litigation Playbook for Challenging FDA/DEA/State Hemp Rules

In 2026, regulated hemp operators are litigating (and defending) compliance frameworks in a legal environment that looks very different than it did even two years ago. Two Supreme Court decisions—Loper Bright Enterprises v. Raimondo (June 28, 2024) and Corner Post, Inc. v. Board of Governors of the Federal Reserve System (July 1, 2024)—shifted the center of gravity in administrative law.

The practical impact is straightforward:

• Courts are less likely to “go along” with an agency’s interpretation just because the statute is ambiguous.
• Old rules can be attacked by new market entrants (or newly-injured plaintiffs) for longer than many compliance teams assumed.
• The quality of the administrative record and the statutory text matters more than ever.

This post is informational only, not legal advice. It’s designed as a post Chevron cannabis litigation strategy guide for hemp-adjacent disputes involving the FDA, DEA, and state regulators.

The new baseline: what Loper Bright and Corner Post changed

Loper Bright: “independent judgment” replaces Chevron

In Loper Bright, the Supreme Court overruled the long-standing Chevron doctrine and held that the Administrative Procedure Act requires courts to exercise independent judgment when deciding whether an agency acted within its statutory authority. The Court relied heavily on APA § 706’s direction that courts “decide all relevant questions of law.”

Read the decision here: https://www.supremecourt.gov/opinions/23pdf/22-451_7m58.pdf

What remains true post-Loper Bright:

• Agencies can still receive respect for persuasive reasoning (often described as Skidmore-type weight).
• Agencies still win cases when Congress clearly delegated authority and the agency builds a solid record.

But what is gone is the reflexive “two-step” Chevron framework that used to rescue many rules even when the statutory best reading was not the agency’s.

Corner Post: a longer runway to challenge old rules

In Corner Post, the Supreme Court held that the six-year statute of limitations for many APA challenges (28 U.S.C. § 2401(a)) generally runs from when the plaintiff is injured by the final agency action—not necessarily from when the rule was first issued.

Read the decision here: https://www.supremecourt.gov/opinions/23pdf/22-1008_1b82.pdf

For hemp businesses, this is a big deal because many federal interpretations that shape the market—especially those embedded in older rules, guidance, or “interim” positions—may become litigation targets again as:

• new brands enter the market,
• new product categories launch,
• payment/marketplace access changes,
• enforcement priorities shift.

Why this hits hemp especially hard (FDA + DEA + state “consumer safety” moves)

Hemp-derived products sit at a complicated regulatory intersection:

• FDA asserts authority through the FD&C Act (food, dietary supplements, cosmetics, drugs, adulteration/misbranding, and therapeutic claims).
• DEA asserts authority through the Controlled Substances Act and its regulations, with recurring disputes over what counts as “synthetic” versus plant-derived.
• States often regulate through public health, agriculture, or consumer protection tools—sometimes by emergency rulemaking or “guidance” that functions like a rule.

With Chevron gone, the common litigation theme becomes: Did the agency exceed what Congress actually authorized?

The 2026 legal flashpoints to watch

1) FDA: enforcement posture without a clear pathway

The FDA continues to maintain that certain cannabinoid ingredients (notably CBD, and also THC in many contexts) are not permitted in foods or dietary supplements under current law because of the “drug exclusion” provisions tied to approved drugs and substantial clinical investigations.

A neutral, official overview of FDA’s CBD posture appears in Congressional Research Service reporting and related explanations of the FD&C Act framework: https://www.everycrsreport.com/reports/R46189.html

Also see FDA’s public page compiling warning letters and enforcement actions: https://www.fda.gov/news-events/public-health-focus/warning-letters-cannabis-derived-products

Post-Loper Bright litigation leverage point:

• If FDA enforcement relies on interpretations that stretch statutory text, courts may be less inclined to defer.
• If FDA’s position is communicated through nonbinding guidance or selective enforcement, challengers may frame claims around final agency action issues, arbitrary-and-capricious enforcement patterns, or equal-treatment arguments.

Business reality: Many disputes are not about whether FDA can act at all, but about whether FDA’s chosen theory (and the record supporting it) matches Congress’s design.

2) DEA: “synthetically derived” THC interpretations and the Farm Bill boundary

The DEA’s 2020 Interim Final Rule implementing the 2018 Farm Bill has been a persistent source of risk and uncertainty, especially around:

• processing “in-process” materials that temporarily exceed thresholds,
• and the agency’s statement that “all synthetically derived tetrahydrocannabinols remain Schedule I” without clearly defining “synthetic.”

Background and discussion of the IFR dispute landscape: https://www.hklaw.com/en/insights/publications/2020/10/hemp-industry-brings-case-against-dea-to-clarify-deas-hemp-rule

DEA’s view has also been reflected in various public letters discussing certain derivatives (for example, THC-O), fueling ongoing “synthetic vs. naturally occurring” debates.

Post-Loper Bright litigation leverage point:

• The best textual reading of the 2018 Farm Bill’s hemp definition and CSA carve-outs becomes central.
• Courts may demand tighter reasoning for why a particular conversion pathway renders a compound “synthetically derived” as a matter of law, rather than chemistry.

Compliance takeaway: Assume DEA risk is not just about what is “in the plant,” but also about manufacturing pathway documentation and how you can prove plant derivation, process controls, and chain of custody.

3) State agencies: emergency rules and “consumer protection shortcuts”

States continue to reshape cannabinoid hemp markets via:

• emergency rulemaking,
• age-gating requirements,
• potency caps,
• prohibitions on “detectable” THC,
• and packaging/serving limitations.

California is a widely cited example where emergency regulations in 2024 triggered fast-moving litigation alleging procedural and authority defects. Summary of that dispute and the legal theories raised: https://www.greenbergglusker.com/the-grass-is-always-greenberg/emergency-regulations-issued-banning-intoxicating-cbd-and-hemp-products-in-california-enforcement-and-legal-challenges

New York’s Office of Cannabis Management also maintains a structured cannabinoid hemp program with licensing and product requirements (including THC concentration limits), illustrating how some states use full programmatic regulation rather than ad hoc enforcement: https://cannabis.ny.gov/cannabinoid-hemp

Post-Loper Bright litigation leverage point:

• Even though Loper Bright is federal administrative law, its “text-first, authority-first” mindset influences how litigators frame challenges to state rules too.
• State-level challenges often hinge on the state APA, emergency rule criteria, legislative delegation boundaries, and dormant Commerce Clause constraints.

“Round two” case law themes businesses should learn from (beyond hemp)

You do not need a hemp-specific decision to build a hemp-specific litigation strategy. Post-Loper Bright decisions across industries are already showing patterns:

Theme A: statutory text is now the main event

Arguments that used to be “Chevron step two” become direct fights over the best reading of a statute, using traditional tools of interpretation.

Theme B: the record matters more, not less

If courts won’t defer on the meaning of the statute, the agency will often pivot to “we had discretion and expertise.” That makes the administrative record and the agency’s explanation under arbitrary-and-capricious review crucial.

Theme C: delegation still saves well-built rules

Not every agency loses after Loper Bright. Where Congress clearly delegates and an agency “fills up the details,” challengers may still face a steep climb.

Theme D: Corner Post reshapes timing and plaintiff selection

Newly-formed businesses or new product lines may become the “fresh injury” vehicles for challenging long-standing rules.

The 2026 litigation playbook: a practical checklist for hemp businesses

This section is the operational heart of a post Chevron cannabis litigation strategy. Even if you never plan to sue anyone, these steps reduce your risk when enforcement or injunctions disrupt the market.

1) Preserve standing early (before you need it)

To sue in federal court, you generally need a concrete injury that is traceable to the challenged action and redressable by the court.

Do now:

• Document specific business harms tied to the rule or policy (lost contracts, delistings, payment processor shutdowns, inventory holds, reformulation costs, destroyed product).
• Keep clean timelines showing when the injury began (Corner Post makes timing more valuable).
• Avoid “self-inflicted” injury narratives where possible; be prepared to show the rule forced the change.

2) Build a reliance record (courts care about real-world disruption)

In fast-moving markets, courts are often balancing equitable factors—especially in preliminary injunctions.

Do now:

• Maintain board or management memos showing good-faith reliance on the legal landscape.
• Track capital investments (equipment, leases, hires) that were made based on then-existing rules.
• Preserve communications showing you sought compliance clarity (counsel letters, regulator outreach, lab validations).

3) Participate in rulemaking comments like a future plaintiff

A strong comment record can become your future litigation record.

Do now:

• Submit comments that are factual and evidence-backed (studies, adverse event monitoring, youth access controls, packaging data).
• Identify statutory authority concerns explicitly (“The statute does not authorize X; Congress used Y language instead.”).
• Propose less restrictive alternatives and quantify impacts.

If you don’t comment, agencies frequently argue you waived key objections or failed to give the agency a fair chance to address issues.

4) Design compliance programs to survive “injunction whiplash”

Litigation outcomes in 2026 can swing quickly: TROs, preliminary injunctions, stays pending appeal, and circuit splits.

Do now:

• Draft SOPs that support rapid product holds, relabeling, or channel shifts.
• Use contract clauses allocating change-in-law, recall, and inventory risk.
• Keep separate SKUs and COAs by jurisdiction to reduce cross-border contamination.

5) Treat “guidance,” FAQs, and letters as signals—not shields

Many enforcement positions are expressed through:

• FAQs,
• warning letters,
• staff letters,
• press releases.

These can be important evidence of agency thinking, but they do not always carry the legal weight of properly adopted rules.

Do now:

• Track what is binding in your jurisdiction (statute/regulation) versus nonbinding.
• When nonbinding positions function like rules, talk to counsel about whether a challenge can target them (or the enforcement action) as final agency action.

6) Prepare for the “synthetic” fight with manufacturing-pathway proof

Whether a compound is treated as plant-derived or synthetic can turn on process steps and chemical conversions.

Do now:

• Maintain chain-of-custody records and batch-level input/output reconciliation.
• Document solvents, catalysts, reagents, and reaction steps.
• Validate your testing labs and keep method SOPs (including isomer and acid forms when applicable).

This is as much a litigation readiness move as it is a quality move.

7) Choose your forum and remedy strategy deliberately

In regulatory litigation, the “where” and “what remedy” questions are often as important as the merits.

Do now:

• Consider whether you need immediate injunctive relief or a long-term merits win.
• Anticipate government arguments about public interest, youth access, adverse events, and confusion in the marketplace.
• Evaluate whether a narrow remedy (as-applied relief) or broader vacatur is realistic.

Timeline signals for 2026: what businesses should calendar

Even without predicting specific lawsuits, compliance teams should calendar the following categories of “litigation triggers”:

• New enforcement priorities (FDA warning letter waves; state inspection surges)
• Emergency rulemaking (often tied to legislative sessions, high-profile incidents, or political pressure)
• Federal statutory changes affecting what qualifies as lawful hemp

On the federal side, multiple policy and advocacy sources have tracked Congressional activity aimed at tightening “intoxicating hemp” definitions, including references to per-container THC limits and total-THC approaches.

For example, NORML summarized appropriations-related developments restricting certain hemp-derived intoxicating products: https://norml.org/news/2025/11/13/federal-lawmakers-approve-funding-bill-restricting-sales-of-certain-hemp-derived-intoxicating-products/

And MPP’s federal policy page has tracked similar developments and timing signals: https://www.mpp.org/policy/federal/

(Always verify with actual enacted statutory text and implementing guidance; secondary summaries can lag or simplify.)

What this means for regulators and investors

For regulators

Post-Loper Bright does not mean agencies lose power; it means agencies must:

• anchor actions in clear statutory authority,
• build an evidence-based record, and
• explain why chosen approaches are reasonable, consistent, and not arbitrary.

Emergency approaches and informal “rule-by-press-release” tactics are more likely to be challenged—and, importantly, more likely to be paused by courts if the record is thin.

For investors and lenders

Due diligence should now include administrative-law risk questions:

• Which revenue lines depend on contested interpretations?
• How quickly can the company reformulate or reroute if a rule is enjoined (or revived on appeal)?
• Does management keep litigation-grade compliance documentation (COAs, SOPs, adverse event logs, complaint handling, labeling substantiation)?

Bottom line: compliance and litigation are now one strategy

In 2026, a winning post Chevron cannabis litigation strategy for hemp businesses is not “sue first.” It is:

• comply defensibly,
• create a record,
• participate in rulemaking, and
• prepare for fast injunction cycles.

If your team can demonstrate disciplined compliance and documented reliance, you are better positioned whether you are:

• challenging a rule,
• defending against enforcement,
• negotiating with regulators,
• or reassuring banks, insurers, and platforms.

Next step: turn this playbook into a living compliance system

If you’re tracking FDA/DEA positions, state rule changes, and court challenges across jurisdictions, manual monitoring breaks quickly.

Use https://www.cannabisregulations.ai/ to centralize cannabis compliance monitoring, licensing intelligence, and regulatory change management—so you can respond to new rules and litigation outcomes before they disrupt operations.